DFO ( DrugBank: - )

---

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	1
284	ダイアモンド・ブラックファン貧血	1
286	遺伝性鉄芽球性貧血	3

46. 悪性関節リウマチ

---

臨床試験数 : 4,356 /  薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03546335 (ClinicalTrials.gov)	October 1, 2018	30/4/2018	Zr-89 Cimzia PET Imaging Rheumatoid Arthritis	Zirconium-89 Certolizumab PET Imaging in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: 89Zr-DFO-CZP	Robert Flavell, MD, PhD	NULL	Suspended	18 Years	N/A	All	10	Phase 1	United States

284. ダイアモンド・ブラックファン貧血

---

臨床試験数 : 36 /  薬物数 : 95 - (DrugBank : 34) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-000766-20-GB (EUCTR)	17/07/2008	13/12/2007	A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions - CORDELIA	A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions - CORDELIA	Beta-thalassemia major (TM) or Diamond Blackfan anemia (DBA) or myelodysplastic syndromes (MDS) (low and INT-1 risk as per the IPSS for MDS) or sideroblastic anemia and myocardial iron overload as indicated by a T2* =6 but not greater than 20 ms, with no symptoms of cardiac dysfunction, and an MRI measured LVEF =56%.	Trade Name: Exjade Product Name: EXJADE Product Code: ICL670 INN or Proposed INN: deferasirox Other descriptive name: EXJADE Trade Name: Exjade Product Name: EXJADE Product Code: ICL670 INN or Proposed INN: deferasirox Other descriptive name: EXJADE Trade Name: Exjade Product Name: EXJADE Product Code: ICL670 INN or Proposed INN: deferasirox Other descriptive name: EXJADE Trade Name: Desferal Product Name: Desferal Product Code: DFO INN or Proposed INN: deferoxamine Trade Name: Desferal Product Name: Desferal Product Code: DFO	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	192	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Italy;United Kingdom

286. 遺伝性鉄芽球性貧血

---

臨床試験数 : 7 /  薬物数 : 20 - (DrugBank : 10) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 43

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-021062-29-GR (EUCTR)	12/04/2011	02/02/2011	Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERION	Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERION	transfusion-dependent patients with TM, DBA or congenital sideroblastic anemia with severe cardiac iron overload MedDRA version: 13.1;Level: LLT;Classification code 10065974;Term: Chronic iron overload;System Organ Class: 10027433 - Metabolism and nutrition disorders	Trade Name: Exjade Product Name: Exjade Product Code: ICL670 INN or Proposed INN: DEFERASIROX Other descriptive name: Exjade Trade Name: Exjade Product Name: Exjade Product Code: ICL670 INN or Proposed INN: DEFERASIROX Other descriptive name: Exjade Trade Name: Exjade Product Name: Exjade Product Code: ICL670 INN or Proposed INN: DEFERASIROX Other descriptive name: Exjade Trade Name: Desferal Product Name: deferoxamine Product Code: DFO INN or Proposed INN: DEFEROXAMINE MESILATE Trade Name: DESFERAL Product Name: deferoxamine Product Code: DFO INN or Proposed INN: DEFEROXAMINE MESILATE	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	45	Phase 2	Greece;Italy;United Kingdom
2	EUCTR2010-021062-29-GB (EUCTR)	21/12/2010	20/10/2010	Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERION	Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERION	transfusion-dependent patients with TM, DBA or congenital sideroblastic anemia with severe cardiac iron overload MedDRA version: 14.1;Level: LLT;Classification code 10065974;Term: Chronic iron overload;System Organ Class: 10027433 - Metabolism and nutrition disorders	Trade Name: Exjade Product Name: Exjade Product Code: ICL670 INN or Proposed INN: DEFERASIROX Other descriptive name: Exjade Trade Name: Exjade Product Name: Exjade Product Code: ICL670 INN or Proposed INN: DEFERASIROX Other descriptive name: Exjade Trade Name: Exjade Product Name: Exjade Product Code: ICL670 INN or Proposed INN: DEFERASIROX Other descriptive name: Exjade Product Name: deferoxamine Product Code: DFO INN or Proposed INN: DEFEROXAMINE MESILATE Product Name: deferoxamine Product Code: DFO INN or Proposed INN: DEFEROXAMINE MESILATE Trade Name: Exjade Product Name: Exjade Product Code: ICL670 INN or Proposed INN: deferasirox INN or Proposed INN: deferasirox INN or Proposed INN: deferasirox	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	45	Phase 2	Greece;Italy;United Kingdom
3	EUCTR2007-000766-20-GB (EUCTR)	17/07/2008	13/12/2007	A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions - CORDELIA	A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions - CORDELIA	Beta-thalassemia major (TM) or Diamond Blackfan anemia (DBA) or myelodysplastic syndromes (MDS) (low and INT-1 risk as per the IPSS for MDS) or sideroblastic anemia and myocardial iron overload as indicated by a T2* =6 but not greater than 20 ms, with no symptoms of cardiac dysfunction, and an MRI measured LVEF =56%.	Trade Name: Exjade Product Name: EXJADE Product Code: ICL670 INN or Proposed INN: deferasirox Other descriptive name: EXJADE Trade Name: Exjade Product Name: EXJADE Product Code: ICL670 INN or Proposed INN: deferasirox Other descriptive name: EXJADE Trade Name: Exjade Product Name: EXJADE Product Code: ICL670 INN or Proposed INN: deferasirox Other descriptive name: EXJADE Trade Name: Desferal Product Name: Desferal Product Code: DFO INN or Proposed INN: deferoxamine Trade Name: Desferal Product Name: Desferal Product Code: DFO	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	192	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Italy;United Kingdom

先頭へ